Skip to content

Effects of Continuous Intake of the Test Food on Improvement of Bowel Movements in Individuals with a Tendency to Constipation

Effects of Continuous Intake of the Test Food on Improvement of Bowel Movements in Individuals with a Tendency to Constipation - Effects of Continuous Intake of the Test Food on Improvement of Bowel Movements in Individuals with a Tendency to Constipation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059228
Enrollment
180
Registered
2026-04-01
Start date
2025-09-30
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Sponsors

PreMedica Inc.
Collaborator
Macromill, Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Male and female participants aged 20 years or older and younger than 65 years at the time of informed consent. (2) Individuals whose bowel movement frequency is between 3 and 5 times per week (3) Individuals who have received sufficient explanation regarding the purpose and content of the study, have the capacity to consent, fully understand the information provided, voluntarily agree to participate, and provide their own consent via electronic informed consent (eConsent).

Exclusion criteria

Exclusion criteria: (1) Individuals using bowel-regulating drugs, such as laxatives or antidiarrheals, including over-the-counter products. (2) Those under treatment for chronic diseases such as diabetes, dyslipidemia, or hypertension. (3) Those with malignant tumors; cerebrovascular, cardiac, hepatic, renal, hematologic, or endocrine disease; gastric or duodenal ulcer under treatment; or a severe medical history. (4) History of major gastrointestinal surgery, including gastrectomy, anastomosis, or intestinal resection, except for appendectomy only. (5) Dermatological conditions such as atopic dermatitis, allergy, eczema, or hypersensitivity under treatment. (6) Cosmetic procedures at the evaluation site within the past 12 weeks, such as collagen, hyaluronic acid, botulinum toxin, or laser, or those unable to refrain during the study. (7) Excessive tanning or inability to avoid intentional sun exposure. (8) Allergy to the test food. (9) Habitual use of health foods, foods with functional claims, probiotics such as yogurt or lactic drinks, or supplements, and unable to stop during the study. (10) Heavy smokers, defined as more than 20 cigarettes per day. (11) Regular alcohol consumers, defined as 60 grams or more of pure alcohol per day, approximately sake three servings, beer 1,500 mL, shochu two servings, or wine 600 mL, on six or more days per week. (12) Extremely irregular sleep or diet, such as shift or night workers. (13) Likely to experience major lifestyle, diet, or exercise changes during the study. (14) Women who are lactating, pregnant, possibly pregnant, or planning pregnancy. (15) Currently in another clinical trial, within the past four weeks, or planning to join during this study. (16) Deemed ineligible by the principal investigator or sub-investigator. (17) Deemed unsuitable by the sponsor.

Design outcomes

Primary

MeasureTime frame
(1) Bowel Movement Questionnaire

Secondary

MeasureTime frame
(1) Skin, Allergic Symptoms, and Fatigue Questionnaire (VAS) (2) Stress Questionnaire (POMS-2 Adult Short Form) (3) Gut Microbiota Analysis (4) Short-Chain Fatty Acids (5) Fecal Metabolites, etc. (6) Skin Viscoelasticity (7) Skin surface hydration (8) Daily Log (Frequency/Severity of Health Concerns/Problems)

Countries

Japan

Contacts

Public ContactYuki Mori

Macromill, Inc. Clinical Trial Department, Life Science Division

yuk_mori@macromill.com03-6716-0700

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026